A Phase II Study for Evaluating Anti-tumor Efficacy of TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma or Pleural Effusion
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 05 Oct 2018 Planned End Date changed from 1 Jul 2019 to 1 Dec 2020.
- 05 Oct 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Dec 2020.
- 11 Jan 2018 New trial record